The ROSELLA trial showed relacorilant plus nab-paclitaxel improved progression-free survival in platinum-resistant ovarian cancer patients. Relacorilant reduced disease progression risk by 30% and ...
Add Yahoo as a preferred source to see more of our stories on Google. As treatment sequencing in ovarian cancer (OC) continues to evolve, an increasing proportion of patients acquire ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...
ARTISTRY-7 trial showed no significant survival benefit for nemvaleukin and Keytruda over chemotherapy in platinum-resistant ovarian cancer. Mural Oncology will cease nemvaleukin development for this ...
Relacorilant plus nab-paclitaxel chemotherapy reduced the risk of disease progression by 30% compared with nab-paclitaxel alone. Treatment with relacorilant plus nab-paclitaxel improved progression ...
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial NRG-GY005 is an ...
The 81 patients with platinum-resistant ovarian cancer (cancer recurrence within six months of receiving a platinum-based chemotherapy) enrolled in the trial were randomized to have the choice of ...
Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...
Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results